We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Effect of Betaine and Folic Acid on Vascular Function in Healthy Humans

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: February 4, 2005
Last Update Posted: August 3, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Wageningen Centre for Food Sciences
February 3, 2005
February 4, 2005
August 3, 2005
October 2002
Not Provided
  • Concentrations of plasma homocysteine in fasting state
  • Vascular function, measured as flow mediated vasodilation, in fasting state
Same as current
Complete list of historical versions of study NCT00102843 on ClinicalTrials.gov Archive Site
  • Lipid concentrations
  • B-vitamins
  • Blood pressure
Same as current
Not Provided
Not Provided
Effect of Betaine and Folic Acid on Vascular Function in Healthy Humans
Effect of Lowering of Fasting Plasma Homocysteine Concentrations Through Supplementation With Betaine or Folic Acid on Vascular Function in Healthy Volunteers
The purpose of this study is to determine whether lowering of fasting homocysteine concentrations improves vascular function in healthy volunteers, irrespective of the homocysteine-lowering agent.

A high plasma homocysteine is a potential risk factor for cardiovascular disease and death. However, it remains uncertain whether homocysteine per se, low status of folate, or other factors related to methionine metabolism are involved in the pathogenesis of cardiovascular disease. Previous studies have shown that a high concentration of homocysteine in blood is related to an impaired vascular function in the arteries, an indicator of cardiovascular disease risk. Virtually all intervention trials used folic acid as a homocysteine-lowering agent, which may however affect vascular function through mechanisms not related to homocysteine. We investigated whether lowering of fasting homocysteine concentrations via supplementation with betaine or folic acid improves vascular function in healthy volunteers, in order to distinguish between effects of folic acid and of homocysteine-lowering per se.

Comparison: We compare the effects of supplementation with folic acid to the effects of betaine, and to the effects of a placebo on plasma homocysteine concentrations and vascular function in healthy humans.

Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Prevention
  • Healthy
  • Cardiovascular Diseases
Procedure: supplementation with folic acid and betaine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2003
Not Provided

Inclusion Criteria:

  • Apparently healthy.
  • Women postmenopausal: two or more years after last menstruation. If the uterus was surgically removed, the women must be 55 years or older.
  • Normal blood values for: hematology, total homocysteine, blood lipids, vitamin B6, vitamin B12, folate, liver enzymes, creatinine.
  • Absence of protein and glucose in urine sample.
  • Body mass index (BMI) between 18 and 30 kg/m2.
  • Good ultrasound visibility of the brachial artery, judged by the sonographer.
  • Willing not to use supplements containing B-vitamins, antioxidant vitamins (A, beta-carotene, C and E) or n-3 fatty acids/fish oil supplements from screening day (>2 months before start of the study) until end of study.
  • Willing not to be blood or plasmapheresis donor from 4 weeks before the screening day, and 4 weeks before the start of the study until the end of study.

Exclusion Criteria:

  • Any chronic or acute disease (e.g. diabetes, renal disease, inflammation).
  • Current, or history of cardiovascular disease.
  • Hypertension.
  • Medical history or surgical events known to interfere with the study.
  • Fasting plasma total homocysteine > 26 micromol/L.
  • Alcohol consumption: more than 21 consumptions /week for women, and more than 28 consumptions/week for men.
  • Weight loss or gain > 2 kg in the month prior to screening.
  • Any special diet (prescribed, slimming, macrobiotic or total vegetarian). Sole exclusion of meat and fish from an otherwise ‘normal’ western diet is allowed.
  • Lactose intolerance.
  • Use of supplements containing B-vitamins more than once weekly in the period from 3 months before the screening day.
  • Participation in any other trial up to 3 months before this study.
  • Use of medication known to interfere with the study outcome.
Sexes Eligible for Study: All
50 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Wageningen Centre for Food Sciences
Not Provided
Study Chair: Petra Verhoef, PhD Wageningen Centre for Food Sciences
Wageningen Centre for Food Sciences
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP